Author: Emma Yasinski

Emma Yasinski

I am a freelance science and medical journalist, fascinated by how the scientific process leads to incredible discoveries, but also can lead to publication bias leaning toward positive findings and minimizing negatives. With a bachelor’s degree in neuroscience from Lafayette College and a Master’s in Science and Medical Journalism from Boston University, I’ve written about clinical trial transparency, organ donation, and basic molecular biology for publications like The Scientist, The Atlantic, Undark.org, Kaiser Health News, and more. At MedShadow, I research and write about the sometimes unexpected ways that medicines can affect us, and what we can do if and when it does.

It took seven years for Madeline Shonka to be diagnosed with lupus. Unfortunately, her struggles didn’t end there.  The side effects of medications for lupus that her healthcare providers prescribed were often debilitating side effects, such as weight gain, rashes and even difficulty managing anger. Then, over time, her physicians tested different, better-suited treatments on Shonka. She found that certain new habits, like light exercise, made a big difference in her quality of life. She then founded Co-immunity, which hosts support groups for patients with chronic illnesses, so that they can share their experiences. What Is Lupus? Lupus is an…

Read More

A new chemotherapy drug promises to treat some patients with pediatric acute lymphoblastic leukemia (ALL) who have been unable to take the other two other chemo medicines because one can cause allergic reactions and the other is frequently in short supply.  This summer, the Food and Drug Administration (FDA) fast-tracked the approval of Rylaze, a newer version of the chemo drug Erwinaze to treat ALL, made by Jazz Pharmaceuticals, which was previously distributed Erwinaze. The agency approved Rylaze based on an ongoing Phase 2/3 trial of about 102 patients, with an average age of 10.  The rare disease ALL affects…

Read More